Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi Source: Eur Respir J 2007; 29: 575-581 Year: 2007
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
Glycopyrrolate exerts medium-duration bronchodilator activity in guinea-pig and human airways Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC) Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Interaction between RPL554 and glycopyrronium bromide in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2 -adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Combination study of tiotropium and olodaterol in human precision-cut lung slices Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2 -agonists in dogs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Interaction between aclidinium bromide and formoterol fumarate in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Impairment of β2 -adrenoceptor agonist relaxation by cytokines is prevented by concomitant glucocorticoid treatment for formoterol but not for salmeterol in mouse trachea Source: Eur Respir J 2007; 30: Suppl. 51, 714s Year: 2007